Grant: Discovery Grants Program - Individual
University of British Columbia
$43,000.00
Advanced Technologies and Platforms for Separation and Characterization of Biological Analytes
EF 2019-20
Résumé
The Biotechnology Industry has become incredibly skilled at producing protein therapeutics to high concentrations in biological reactors. As a result, more than ever the primary cost and challenges associated with manufacturing these life-saving drugs reside in the processes required to purify them safely and economically. Major advances in existing purification technologies, as well as entirely new purification concepts, are needed right now to align product recovery capabilities with the tremendous advances seen in cell-culture technology. Manufacturing costs must be reduced to levels that help abate the recognized rising costs of healthcare and bring the products of what is now a $400 billion US per annum industry in tune with the Affordable Care Act. The objective of my NSERC DG supported research program is to create a number of these required capabilities and then develop each to a level where its adoption by industry is actually realized. New packing for industrial chromatography columns will be created that allows for much higher throughputs while preserving the high yields and product purities that make chromatography the preferred method for isolating biologic drugs at manufacturing scales. An entirely new mode of chromatography will be developed that may allow industry to process therapeutic proteins that have historically been very difficult to purify. New technology will be created to enable industry to more closely monitor and control the quality of the drug product as it is being manufactured. And finally, a new pipeline that provides for rapid development of effective chromatographic purification of orphan drugs - biologics used to treat rare but debilitating diseases - will be established. The program is therefore expected to provide important fundamental and operational advances in the instrumentation and methods used to manufacture life-saving biologic therapeutics.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2016-04612
Name nom
Haynes, Charles
Department département
Chemical and Biological Engineering
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2016
Award amount
43000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Installment
inst:4 - 5
Partie
4
Nb partie
5
Application title
Advanced Technologies and Platforms for Separation and Characterization of Biological Analytes
Keyword
NSERC
Application summary
The Biotechnology Industry has become incredibly skilled at producing protein therapeutics to high concentrations in biological reactors. As a result, more than ever the primary cost and challenges associated with manufacturing these life-saving drugs reside in the processes required to purify them safely and economically. Major advances in existing purification technologies, as well as entirely new purification concepts, are needed right now to align product recovery capabilities with the tremendous advances seen in cell-culture technology. Manufacturing costs must be reduced to levels that help abate the recognized rising costs of healthcare and bring the products of what is now a $400 billion US per annum industry in tune with the Affordable Care Act. The objective of my NSERC DG supported research program is to create a number of these required capabilities and then develop each to a level where its adoption by industry is actually realized. New packing for industrial chromatography columns will be created that allows for much higher throughputs while preserving the high yields and product purities that make chromatography the preferred method for isolating biologic drugs at manufacturing scales. An entirely new mode of chromatography will be developed that may allow industry to process therapeutic proteins that have historically been very difficult to purify. New technology will be created to enable industry to more closely monitor and control the quality of the drug product as it is being manufactured. And finally, a new pipeline that provides for rapid development of effective chromatographic purification of orphan drugs - biologics used to treat rare but debilitating diseases - will be established. The program is therefore expected to provide important fundamental and operational advances in the instrumentation and methods used to manufacture life-saving biologic therapeutics.